BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 38692507)

  • 1. The deubiquitinase USP5 promotes cholangiocarcinoma progression by stabilizing YBX1.
    Ning F; Du L; Li J; Wu T; Zhou J; Chen Z; Hu X; Zhang Y; Luan X; Xin H; Yuan C; Zhang X
    Life Sci; 2024 Jul; 348():122674. PubMed ID: 38692507
    [TBL] [Abstract][Full Text] [Related]  

  • 2. YBX1 promotes stemness and cisplatin insensitivity in intrahepatic cholangiocarcinoma via the AKT/β-catenin axis.
    Shi X; Hu Z; Bai S; Zong C; Xue H; Li Y; Li F; Chen L; Xuan J; Xia Y; Wei L; Shen F; Wang K
    J Gene Med; 2024 May; 26(5):e3689. PubMed ID: 38676365
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A PLCB1-PI3K-AKT Signaling Axis Activates EMT to Promote Cholangiocarcinoma Progression.
    Liang S; Guo H; Ma K; Li X; Wu D; Wang Y; Wang W; Zhang S; Cui Y; Liu Y; Sun L; Zhang B; Xin M; Zhang N; Zhou H; Liu Y; Wang J; Liu L
    Cancer Res; 2021 Dec; 81(23):5889-5903. PubMed ID: 34580062
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bmi1 facilitates the progression of cholangiocarcinoma by inhibiting Foxn2 expression dependent on a histone H2A ubiquitination manner.
    Song Y; Lian S; Fan H; Ma C; Zheng L; Huang F; Huang S; Tang Y; Shi A; Shu L; Zhao L; Xu Y; Guo S; Liu Z; Zhang Z
    Cancer Lett; 2024 Jun; 592():216921. PubMed ID: 38705565
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Knockdown of tripartite motif 59 (TRIM59) inhibits proliferation in cholangiocarcinoma via the PI3K/AKT/mTOR signalling pathway.
    Shen H; Zhang J; Zhang Y; Feng Q; Wang H; Li G; Jiang W; Li X
    Gene; 2019 May; 698():50-60. PubMed ID: 30822475
    [TBL] [Abstract][Full Text] [Related]  

  • 6. USP5 promotes epithelial-mesenchymal transition by stabilizing SLUG in hepatocellular carcinoma.
    Meng J; Ai X; Lei Y; Zhong W; Qian B; Qiao K; Wang X; Zhou B; Wang H; Huai L; Zhang X; Han J; Xue Y; Liang Y; Zhou H; Chen S; Sun T; Yang C
    Theranostics; 2019; 9(2):573-587. PubMed ID: 30809294
    [No Abstract]   [Full Text] [Related]  

  • 7. RPL35A promotes the progression of cholangiocarcinoma by mediating HSPA8 ubiquitination.
    Zhang C; Wang Y; Wu G; Sun N; Bai H; Li X; Han S; Zhou H; Qi R; Zhang J
    Biol Direct; 2024 Feb; 19(1):16. PubMed ID: 38395908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MicroRNA-494-dependent WDHDI inhibition suppresses epithelial-mesenchymal transition, tumor growth and metastasis in cholangiocarcinoma.
    Liu B; Hu Y; Qin L; Peng XB; Huang YX
    Dig Liver Dis; 2019 Mar; 51(3):397-411. PubMed ID: 30314946
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tetraspanin 1 promotes epithelial-to-mesenchymal transition and metastasis of cholangiocarcinoma via PI3K/AKT signaling.
    Wang Y; Liang Y; Yang G; Lan Y; Han J; Wang J; Yin D; Song R; Zheng T; Zhang S; Pan S; Liu X; Zhu M; Liu Y; Cui Y; Meng F; Zhang B; Liang S; Guo H; Liu Y; Hassan MK; Liu L
    J Exp Clin Cancer Res; 2018 Dec; 37(1):300. PubMed ID: 30514341
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GSG2 knockdown suppresses cholangiocarcinoma progression by regulating cell proliferation, apoptosis and migration.
    Zhou J; Nie W; Yuan J; Zhang Z; Mi L; Wang C; Huang R
    Oncol Rep; 2021 Jun; 45(6):. PubMed ID: 33846801
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stabilization of KPNB1 by deubiquitinase USP7 promotes glioblastoma progression through the YBX1-NLGN3 axis.
    Li J; Zhang B; Feng Z; An D; Zhou Z; Wan C; Hu Y; Sun Y; Wang Y; Liu X; Wei W; Yang X; Meng J; Che M; Sheng Y; Wu B; Wen L; Huang F; Li Y; Yang K
    J Exp Clin Cancer Res; 2024 Jan; 43(1):28. PubMed ID: 38254206
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long non-coding RNA MIR22HG inhibits cell proliferation and migration in cholangiocarcinoma by negatively regulating the Wnt/β-catenin signaling pathway.
    Hu X; Tan Z; Yang Y; Yang P
    J Gene Med; 2019 May; 21(5):e3085. PubMed ID: 30856284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Forced overexpression of FBP1 inhibits proliferation and metastasis in cholangiocarcinoma cells via Wnt/β-catenin pathway.
    Zhao W; Yang S; Chen J; Zhao J; Dong J
    Life Sci; 2018 Oct; 210():224-234. PubMed ID: 30193944
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MicroRNA-21 regulates biological behavior by inducing EMT in human cholangiocarcinoma.
    Liu Z; Jin ZY; Liu CH; Xie F; Lin XS; Huang Q
    Int J Clin Exp Pathol; 2015; 8(5):4684-94. PubMed ID: 26191158
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Upregulated LASP-1 correlates with a malignant phenotype and its potential therapeutic role in human cholangiocarcinoma.
    Zhang H; Li Z; Chu B; Zhang F; Zhang Y; Ke F; Chen Y; Xu Y; Liu S; Zhao S; Liang H; Weng M; Wu X; Li M; Wu W; Quan Z; Liu Y; Zhang Y; Gong W
    Tumour Biol; 2016 Jun; 37(6):8305-15. PubMed ID: 26729195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SP1-induced HOXD-AS1 promotes malignant progression of cholangiocarcinoma by regulating miR-520c-3p/MYCN.
    Li J; Jiang X; Li Z; Huang L; Ji D; Yu L; Zhou Y; Cui Y
    Aging (Albany NY); 2020 Aug; 12(16):16304-16325. PubMed ID: 32857725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Up-regulated LINC00261 predicts a poor prognosis and promotes a metastasis by EMT process in cholangiocarcinoma.
    Gao J; Qin W; Kang P; Xu Y; Leng K; Li Z; Huang L; Cui Y; Zhong X
    Pathol Res Pract; 2020 Jan; 216(1):152733. PubMed ID: 31812439
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FUT4 promotes the progression of Cholangiocarcinoma by modulating epithelial-mesenchymal transition.
    Liu E; Qian X; He Y; Chen K
    Cell Cycle; 2024 Jan; 23(2):218-231. PubMed ID: 38466946
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumor activity of celastrol by inhibition of proliferation, invasion, and migration in cholangiocarcinoma via PTEN/PI3K/Akt pathway.
    Zhu B; Wei Y
    Cancer Med; 2020 Jan; 9(2):783-796. PubMed ID: 31957323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncogenic Role of the NFATC2/NEDD4/FBP1 Axis in Cholangiocarcinoma.
    Zhao W; Zhao J; Li K; Hu Y; Yang D; Tan B; Shi J
    Lab Invest; 2023 Sep; 103(9):100193. PubMed ID: 37285922
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.